Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen Messer

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
Cell Stem Cell|June 3, 2018
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic LeukemiaMichael Y Choi, George F Widhopf, Emanuela M Ghia, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 10, 2019
Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibodySuping Zhang, Han Zhang, Emanuela M Ghia, et al.
Journal of Translational Medicine|May 30, 2020
Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancerStephen T Ryan, Jing Zhang, Danielle N Burner, et al.
Cancer Research|April 21, 2011
Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancerVered Padler-Karavani, Nancy Hurtado-Ziola, Minya Pu, et al.
EGEMS (Washington, DC)|June 9, 2018
A Framework for Leveraging "Big Data" to Advance Epidemiology and Improve Quality: Design of the VA Colonoscopy CollaborativeSamir Gupta, Lin Liu, Olga V Patterson, et al.
Cell Reports|September 26, 2019
Oligogenic Effects of 16p11.2 Copy-Number Variation on Craniofacial DevelopmentYuqi Qiu, Thomas Arbogast, Sandra Martin Lorenzo, et al.
Breast Cancer Research : BCR|February 26, 2024
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancerRebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, et al.
Oncotarget|October 6, 2017
A cerebrospinal fluid microRNA signature as biomarker for glioblastomaJohnny C Akers, Wei Hua, Hongying Li, et al.
The Lancet. Oncology|May 14, 2021
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G Sacco, Ruifeng Chen, Francis P Worden, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentHoward H Feldman, Karen Messer, Jing Zhang, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
Cell Stem Cell|June 3, 2018
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic LeukemiaMichael Y Choi, George F Widhopf, Emanuela M Ghia, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 10, 2019
Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibodySuping Zhang, Han Zhang, Emanuela M Ghia, et al.
Journal of Translational Medicine|May 30, 2020
Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancerStephen T Ryan, Jing Zhang, Danielle N Burner, et al.
Cancer Research|April 21, 2011
Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancerVered Padler-Karavani, Nancy Hurtado-Ziola, Minya Pu, et al.
EGEMS (Washington, DC)|June 9, 2018
A Framework for Leveraging "Big Data" to Advance Epidemiology and Improve Quality: Design of the VA Colonoscopy CollaborativeSamir Gupta, Lin Liu, Olga V Patterson, et al.
Cell Reports|September 26, 2019
Oligogenic Effects of 16p11.2 Copy-Number Variation on Craniofacial DevelopmentYuqi Qiu, Thomas Arbogast, Sandra Martin Lorenzo, et al.
Breast Cancer Research : BCR|February 26, 2024
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancerRebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, et al.
Oncotarget|October 6, 2017
A cerebrospinal fluid microRNA signature as biomarker for glioblastomaJohnny C Akers, Wei Hua, Hongying Li, et al.
The Lancet. Oncology|May 14, 2021
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G Sacco, Ruifeng Chen, Francis P Worden, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentHoward H Feldman, Karen Messer, Jing Zhang, et al.
Pageof 18